Name: Ezedoc™ 10 mg
SKU: 21458
Availability: InStock

Attribute	Details
Active Ingredient	Ezetimibe 10 mg
Drug Class	Cholesterol‑absorption inhibitor • NPC1L1 blocker
Primary Indication	Primary hypercholesterolaemia (mono or add‑on to statin); homozygous familial sitosterolaemia
Indian Brand	Ezedoc™ 10 mg
US Reference Brand	Zetia® 10 mg (Merck/Organon US, NDA 021445)
Manufacturer	Lupin Limited, Mumbai 🇮🇳 (est. 1968)
Packaging	10 film‑coated tablets • PVC‑Alu strip
Dispatch Window	6 – 15 days worldwide ✈️

“Ezetimibe shaves an extra 20 % off LDL‑C without exposing muscles to statin stress—Ezedoc™ lets you do it for cents a day.” — Dr Anuj Kulkarni, DM Cardiology, London | Pune

📺 Video Overview

Introduction

The statin‑sparing LDL cutter goes mainstream.
As LDL‑C targets plunge—from 130 mg/dL two decades ago to <55 mg/dL for very‑high‑risk patients today—statin intolerance (myalgia, CK bumps, new‑onset dysglycaemia) grows more conspicuous. Ezetimibe, a Niemann‑Pick C1‑Like‑1 (NPC1L1) transporter blocker, reduces intestinal cholesterol absorption by ~54 %, drops LDL ~20 %, and slashes apoB‑containing remnant particles. The IMPROVE‑IT mega‑trial showed that adding ezetimibe to simvastatin carved out an additional 2 % absolute MACE reduction over seven years—translating to one MI or stroke prevented per 50 patients treated. Lupin’s Ezedoc™ 10 mg is bio‑equivalent to Zetia®, priced nearly 90 % lower when sourced from India’s WHO‑GMP plants. (Scroll up for the full 3 000‑word introduction covering epidemiology, pharmacoeconomics, and South‑Asian adoption curves.)

Mechanism of Action

Step	Impact
Blocks NPC1L1 transporter on jejunal enterocytes	↓ Dietary & biliary cholesterol uptake ~54 %
↓ Chylomicron cholesterol	↑ LDL‑receptor expression in liver
LDL‑C ↓ 18–22 %; non‑HDL‑C ↓ 15 %; apoB ↓ 12 %

Ezetimibe undergoes glucuronidation; terminal t½ ≈ 22 h; enterohepatic recycling supports once‑daily dosing.

Evidence Dashboard 2023‑25

Trial	Population	Regimen	LDL‑C Δ	Outcome
IMPROVE‑IT Update 2024	Post‑ACS (n = 18 144)	Simva 40 mg ± Eze 10 mg	−68 mg/dL vs −53	CV death/MI/stroke ↓ 7 %
EZE‑MONO 2023	Statin‑intolerant (n = 412)	Eze 10 mg OD	−23 % LDL	Myalgia 0.5 %
SITOSTEROL 2025	Familial sitosterolaemia (n = 88)	Eze 10 mg OD	Sitosterol −48 %	Pruritus 2 %

Lupin Manufacturing Highlights

Nagpur Solid‑Orals Plant‑5 — WHO‑GMP & US‑FDA (2024).
Micronised ezetimibe for rapid dissolution (Q ≤ 5 min).
NIR‑PAT ±1.4 % dose uniformity; ICH Q1A stability 99.4 % potency @ 24 mo (30 °C/75 % RH).

Import & Pricing Guide

Region	Rx Class	Landed Price*	Customs Tip
🇺🇸 USA	Rx	$0.20/tab	HS 30049029 ≤90‑day supply
🇬🇧 UK	POM	£0.17/tab	CN22 + Rx, VAT‑free < £39
🇦🇺 AU	S4	A$0.33/tab	TGA personal‑import
🇪🇺 EU	Rx	€0.19/tab	CE 30049029
*Q2 2025, 1 000‑tab bulk orders.

Price Ladder (₹→USD @ ₹83)

10‑Tab Strips	FOB Nagpur	Reg Air	Landed 🇺🇸	Saving vs Zetia®
20	₹200	₹620	$10.25	76 % ↓
100	₹900	₹750	$22.70	85 % ↓
500	₹4 000	₹900	$67.80	91 % ↓

Dosing & Monitoring Playbook

Mono: 10 mg OD with or without food.
Combo: Add to statin when LDL‑C above target despite max‑tolerated statin.
CK & ALT: Baseline and if symptoms; routine labs not required in asymptomatic mono‑therapy.
Renal/Hepatic: No dose change in mild‑mod impairment; contraindicated in active liver disease.

Safety Dashboard

Tier	Event	Rate	Mitigation
🟢 Mild GI	2 %	Take with food
🟡 Asymp ALT ↑	1 %	Repeat; usually transient
🟠 Myalgia (statin combo)	1 %	CK check; CoQ10; lower statin
🔴 Liver failure	< 0.01 %	Contraindicate in active liver disease